Toll-like receptor signaling is functional in immune cells of the endangered Tasmanian devil

Developmental and Comparative Immunology

Volumn 53, Issue 1, 2015, Pages 123-133

  Patchett, Amanda L ^a   Latham, Roger ^b   Brettingham Moore, Kate H ^b   Tovar, Cesar ^a   Lyons, A Bruce ^b   Woods, Gregory M ^a,b  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Adjuvant; Devil facial tumour disease; Innate immunity; Marsupial; Tasmanian devil; Toll like receptor

Indexed keywords

ADJUVANT; BETA INTERFERON; CPG 1585; CPG 2395; FLAGELLIN; IMIQUIMOD; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; POLYINOSINIC POLYCYTIDYLIC ACID; PROFILIN; RNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 13; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR AGONIST; TUMOR VACCINE; UNCLASSIFIED DRUG; INTERLEUKIN 12P35;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CONTROLLED STUDY; DEVIL FACIAL TUMOR DISEASE; ENDANGERED SPECIES; FACE TUMOR; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; INNATE IMMUNITY; MARSUPIAL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ISOLATION; SIGNAL TRANSDUCTION; TASMANIAN DEVIL; TUMOR CELL; TUMOR IMMUNITY; AGONISTS; ANIMAL; BIOSYNTHESIS; FACIAL NEOPLASMS; IMMUNOLOGY; MONONUCLEAR CELL;

METATHERIA; SARCOPHILUS HARRISII;

ANIMALS; FACIAL NEOPLASMS; IMMUNITY, INNATE; INTERFERON-BETA; INTERLEUKIN-12 SUBUNIT P35; INTERLEUKIN-1ALPHA; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MARSUPIALIA; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84937541775     PISSN: 0145305X     EISSN: 18790089     Source Type: Journal    
DOI: 10.1016/j.dci.2015.07.003     Document Type: Article

References (69)

1. Adams S., Kozhaya L., Martiniuk F., Meng T.C., Chiriboga L., Liebes L., Hochman T., Shuman N., Axelrod D., Speyer J., Novik Y., Tiersten A., Goldberg J.D., Formenti S.C., Bhardwaj N., Unutmaz D., Demaria S. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin. Cancer Res. 2012, 18:6748-6757.
2. Applequist S.E., Wallin R.P., Ljunggren H.G. Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines. Int. Immunol. 2002, 14:1065-1074.
3. Banerjee A., Gugasyan R., McMahon M., Gerondakis S. Diverse Toll-like receptors utilize Tpl2 to activate extracellular signal-regulated kinase (ERK) in hemopoietic cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:3274-3279.
4. Basith S., Manavalan B., Yoo T.H., Kim S.G., Choi S. Roles of toll-like receptors in cancer: a double-edged sword for defense and offense. Arch. Pharm. Res. 2012, 35:1297-1316.
5. Bauer M., Redecke V., Ellwart J.W., Scherer B., Kremer J.P., Wagner H., Lipford G.B. Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. J.Immunol. 2001, 166:5000-5007.
6. Blander J.M., Medzhitov R. Regulation of phagosome maturation by signals from toll-like receptors. Science 2004, 304:1014-1018.
7. Brown G.K., Kreiss A., Lyons A.B., Woods G.M. Natural killer cell mediated cytotoxic responses in the Tasmanian devil. PLoS One 2011, 6:e24475.
8. Brozek C.M., Kaleta E.W., Kusewitt D.F., Ley R.D. Proliferative responses of lymphocytes to mitogens in the gray, short-tailed opossum, Monodelphis domestica. Vet. Immunol. Immunopathol. 1992, 31:11-19.
9. Casares N., Pequignot M.O., Tesniere A., Ghiringhelli F., Roux S., Chaput N., Schmitt E., Hamai A., Hervas-Stubbs S., Obeid M., Coutant F., Metivier D., Pichard E., Aucouturier P., Pierron G., Garrido C., Zitvogel L., Kroemer G. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J.Exp. Med. 2005, 202:1691-1701.
10. Cowled C., Baker M., Tachedjian M., Zhou P., Bulach D., Wang L.F. Molecular characterisation of Toll-like receptors in the black flying fox Pteropus alecto. Dev. Comp. Immunol. 2011, 35:7-18.
11. Cui J., Cheng Y., Belov K. Diversity in the Toll-like receptor genes of the Tasmanian devil (Sarcophilus harrisii). Immunogenetics 2015, 67:195-201.
12. Cui J., Frankham G.J., Johnson R.N., Polkinghorne A., Timms P., O'Meally D., Cheng Y., Belov K. SNP marker discovery in koala TLR genes. PLoS One 2015, 10:e0121068.
13. Deakin J.E., Bender H.S., Pearse A.M., Rens W., O'Brien P.C., Ferguson-Smith M.A., Cheng Y., Morris K., Taylor R., Stuart A., Belov K., Amemiya C.T., Murchison E.P., Papenfuss A.T., Graves J.A. Genomic restructuring in the Tasmanian devil facial tumour: chromosome painting and gene mapping provide clues to evolution of a transmissible tumour. PLoS Genet. 2012, 8:e1002483.
14. Flies A.S., Maksimoski M.T., Mansfield L.S., Weldele M.L., Holekamp K.E. Characterization of Toll-like receptors 1-10 in spotted hyenas. Vet. Res. Commun. 2014, 38:165-170.
15. Galluzzi L., Vacchelli E., Eggermont A., Fridman W.H., Galon J., Sautes-Fridman C., Tartour E., Zitvogel L., Kroemer G. Trial Watch: experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012, 1:699-716.
16. Hamede R., McCallum H., Jones M. Seasonal, demographic and density-related patterns of contact between Tasmanian devils (Sarcophilus harrisii): Implications for transmission of devil facial tumour disease. Austral Ecol. 2008, 33:614-622.
17. Hawkins C., Baars C., Hesterman H., Hocking G., Jones M., Lazenby B., Mann D., Mooney N., Pemberton D., Pyecroft S. Emerging disease and population decline of an island endemic, the Tasmanian devil (Sarcophilus harrisii). Biol. Conserv. 2006, 131:307-324.
18. He W., Liu Q., Wang L., Chen W., Li N., Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol. Immunol. 2007, 44:2850-2859.
19. Hemmi H., Kaisho T., Takeuchi O., Sato S., Sanjo H., Hoshino K., Horiuchi T., Tomizawa H., Takeda K., Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 2002, 3:196-200.
20. Hemmi H., Takeuchi O., Sato S., Yamamoto M., Kaisho T., Sanjo H., Kawai T., Hoshino K., Takeda K., Akira S. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J.Exp. Med. 2004, 199:1641-1650.
21. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdörfer B., Giese T., Endres S., Hartmann G. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG Oligodeoxynucleotides. J.Immunol. 2002, 168:4531-4537.
22. Howson L.J., Morris K.M., Kobayashi T., Tovar C., Kreiss A., Papenfuss A.T., Corcoran L., Belov K., Woods G.M. Identification of dendritic cells, B cell and T cell subsets in Tasmanian devil lymphoid tissue; evidence for poor immune cell infiltration into devil facial tumors. Anat. Rec. (Hoboken) 2014, 297:925-938.
23. Inoue H., Tani K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ. 2014, 21:39-49.
24. Kaiser W.J., Sridharan H., Huang C., Mandal P., Upton J.W., Gough P.J., Sehon C.A., Marquis R.W., Bertin J., Mocarski E.S. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J.Biol. Chem. 2013, 288:31268-31279.
25. Kassianos A.J., Jongbloed S.L., Hart D.N., Radford K.J. Isolation of human blood DC subtypes. Methods Mol. Biol. 2010, 595:45-54.
26. Kreiss A., Brown G.K., Tovar C., Lyons A.B., Woods G.M. Evidence for induction of humoral and cytotoxic immune responses against devil facial tumor disease cells in Tasmanian devils (Sarcophilus harrisii) immunized with killed cell preparations. Vaccine 2015, 10.1016/j.vaccine.2015.01.039.
27. Kreiss A., Cheng Y., Kimble F., Wells B., Donovan S., Belov K., Woods G.M. Allorecognition in the Tasmanian devil (Sarcophilus harrisii), an endangered marsupial species with limited genetic diversity. PLoS One 2011, 6:e22402.
28. Kreiss A., Fox N., Bergfeld J., Quinn S.J., Pyecroft S., Woods G.M. Assessment of cellular immune responses of healthy and diseased Tasmanian devils (Sarcophilus harrisii). Dev. Comp. Immunol. 2008, 32:544-553.
29. Kreiss A., Obendorf D.L., Hemsley S., Canfield P.J., Woods G.M. Ahistological and immunohistochemical analysis of lymphoid tissues of the Tasmanian devil. Anat. Rec. (Hoboken) 2009, 292:611-620.
30. Kreiss A., Wells B., Woods G.M. The humoral immune response of the Tasmanian devil (Sarcophilus harrisii) against horse red blood cells. Vet. Immunol. Immunopathol. 2009, 130:135-137.
31. Krug A., Towarowski A., Britsch S., Rothenfusser S., Hornung V., Bals R., Giese T., Engelmann H., Endres S., Krieg A.M., Hartmann G. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur. J. Immunol. 2001, 31:3026-3037.
32. Krutzik S.R., Tan B., Li H., Ochoa M.T., Liu P.T., Sharfstein S.E., Graeber T.G., Sieling P.A., Liu Y.J., Rea T.H., Bloom B.R., Modlin R.L. TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat. Med. 2005, 11:653-660.
33. Lehner M., Morhart P., Stilper A., Petermann D., Weller P., Stachel D., Holter W. Efficient chemokine-dependent migration and primary and secondary IL-12 secretion by human dendritic cells stimulated through Toll-like receptors. J.Immunother. 2007, 30:312-322.
34. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
35. Loh R., Hayes D., Mahjoor A., O'Hara A., Pyecroft S., Raidal S. The immunohistochemical characterization of devil facial tumor disease (DFTD) in the Tasmanian Devil (Sarcophilus harrisii). Vet. Pathol. 2006, 43:896-903.
36. Luo Q., Hu S., Yan M., Sun Z., Chen W., Chen F. Activation of Toll-like receptor 3 induces apoptosis of oral squamous carcinoma cells invitro and invivo. Int. J. Biochem. Cell Biol. 2012, 44:1266-1275.
37. McCallum H., Jones M., Hawkins C., Hamede R., Lachish S., Sinn D.L., Beeton N., Lazenby B. Transmission dynamics of Tasmanian devil facial tumor disease may lead to disease-induced extinction. Ecology 2009, 90:3379-3392.
38. Medzhitov R., Preston-Hurlburt P., Janeway C.A. Ahuman homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997, 388:394-397.
39. Medzhitov R., Preston-Hurlburt P., Kopp E., Stadlen A., Chen C., Ghosh S., Janeway C.A. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol. Cell 1998, 2:253-258.
40. Miconnet I., Koenig S., Speiser D., Krieg A., Guillaume P., Cerottini J.C., Romero P. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J.Immunol. 2002, 168:1212-1218.
41. Murchison E.P., Schulz-Trieglaff O.B., Ning Z., Alexandrov L.B., Bauer M.J., Fu B., Hims M., Ding Z., Ivakhno S., Stewart C., Ng B.L., Wong W., Aken B., White S., Alsop A., Becq J., Bignell G.R., Cheetham R.K., Cheng W., Connor T.R., Cox A.J., Feng Z.P., Gu Y., Grocock R.J., Harris S.R., Khrebtukova I., Kingsbury Z., Kowarsky M., Kreiss A., Luo S., Marshall J., McBride D.J., Murray L., Pearse A.M., Raine K., Rasolonjatovo I., Shaw R., Tedder P., Tregidgo C., Vilella A.J., Wedge D.C., Woods G.M., Gormley N., Humphray S., Schroth G., Smith G., Hall K., Searle S.M., Carter N.P., Papenfuss A.T., Futreal P.A., Campbell P.J., Yang F., Bentley D.R., Evers D.J., Stratton M.R. Genome sequencing and analysis of the Tasmanian devil and its transmissible cancer. Cell 2012, 148:780-791.
42. Murchison E.P., Tovar C., Hsu A., Bender H.S., Kheradpour P., Rebbeck C.A., Obendorf D., Conlan C., Bahlo M., Blizzard C.A., Pyecroft S., Kreiss A., Kellis M., Stark A., Harkins T.T., Marshall Graves J.A., Woods G.M., Hannon G.J., Papenfuss A.T. The Tasmanian devil transcriptome reveals Schwann cell origins of a clonally transmissible cancer. Science 2010, 327:84-87.
43. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 2005, 6:769-776.
44. Ninomiya-Tsuji J., Kishimoto K., Hiyama A., Inoue J., Cao Z., Matsumoto K. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 1999, 398:252-256.
45. Obeid M., Tesniere A., Ghiringhelli F., Fimia G.M., Apetoh L., Perfettini J.L., Castedo M., Mignot G., Panaretakis T., Casares N., Metivier D., Larochette N., van Endert P., Ciccosanti F., Piacentini M., Zitvogel L., Kroemer G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 2007, 13:54-61.
46. Paone A., Starace D., Galli R., Padula F., De Cesaris P., Filippini A., Ziparo E., Riccioli A. Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis 2008, 29:1334-1342.
47. Pearse A.M., Swift K. Allograft theory: transmission of devil facial-tumour disease. Nature 2006, 439:549.
48. Pinfold T.L., Brown G.K., Bettiol S.S., Woods G.M. Mouse model of devil facial tumour disease establishes that an effective immune response can be generated against the Cancer cells. Front. Immunol. 2014, 5:251.
49. Qian Y., Commane M., Ninomiya-Tsuji J., Matsumoto K., Li X. IRAK-mediated translocation of TRAF6 and TAB2 in the interleukin-1-induced activation of NFkappa B. J.Biol. Chem. 2001, 276:41661-41667.
50. Riccardi C., Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat. Protoc. 2006, 1:1458-1461.
51. Roach J.C., Glusman G., Rowen L., Kaur A., Purcell M.K., Smith K.D., Hood L.E., Aderem A. The evolution of vertebrate Toll-like receptors. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9577-9582.
52. Schnare M., Barton G.M., Holt A.C., Takeda K., Akira S., Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. 2001, 2:947-950.
53. Schon M., Bong A.B., Drewniok C., Herz J., Geilen C.C., Reifenberger J., Benninghoff B., Slade H.B., Gollnick H., Schon M.P. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J.Natl. Cancer Inst. 2003, 95:1138-1149.
54. Schon M.P., Wienrich B.G., Drewniok C., Bong A.B., Eberle J., Geilen C.C., Gollnick H., Schon M. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J.Invest Dermatol 2004, 122:1266-1276.
55. Schwarz K., Storni T., Manolova V., Didierlaurent A., Sirard J.C., Rothlisberger P., Bachmann M.F. Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur. J. Immunol. 2003, 33:1465-1470.
56. Siddle H.V., Kreiss A., Tovar C., Yuen C.K., Cheng Y., Belov K., Swift K., Pearse A.M., Hamede R., Jones M.E., Skjodt K., Woods G.M., Kaufman J. Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:5103-5108.
57. Sohn K.C., Li Z.J., Choi D.K., Zhang T., Lim J.W., Chang I.K., Hur G.M., Im M., Lee Y., Seo Y.J., Lee J.H., Kim C.D. Imiquimod induces apoptosis of squamous cell carcinoma (SCC) cells via regulation of A20. PLoS One 2014, 9:e95337.
58. Song E.J., Kang M.J., Kim Y.S., Kim S.M., Lee S.E., Kim C.H., Kim D.J., Park J.H. Flagellin promotes the proliferation of gastric cancer cells via the Toll-like receptor 5. Int. J. Mol. Med. 2011, 28:115-119.
59. Tirumurugaan K.G., Dhanasekaran S., Raj G.D., Raja A., Kumanan K., Ramaswamy V. Differential expression of toll-like receptor mRNA in selected tissues of goat (Capra hircus). Vet. Immunol. Immunopathol. 2010, 133:296-301.
60. Vacchelli E., Eggermont A., Sautes-Fridman C., Galon J., Zitvogel L., Kroemer G., Galluzzi L. Trial Watch: toll-like receptor agonists for cancer therapy. Oncoimmunology 2013, 2:e25238.
61. Vahanan B.M., Raj G.D., Pawar R.M., Gopinath V.P., Raja A., Thangavelu A. Expression profile of toll like receptors in a range of water buffalo tissues (Bubalus bubalis). Vet. Immunol. Immunopathol. 2008, 126:149-155.
62. Vollmer J., Weeratna R., Payette P., Jurk M., Schetter C., Laucht M., Wader T., Tluk S., Liu M., Davis H.L., Krieg A.M. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 2004, 34:251-262.
63. Warger T., Osterloh P., Rechtsteiner G., Fassbender M., Heib V., Schmid B., Schmitt E., Schild H., Radsak M.P. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses invivo. Blood 2006, 108:544-550.
64. Wilkinson R., Kotlarski I., Barton M., Phillips P. Isolation of koala lymphoid cells and their invitro responses to mitogens. Vet. Immunol. Immunopathol. 1992, 31:21-33.
65. Woods G., Kreiss A., Belov K., Siddle H., Obendorf D., Muller H.K. The immune response of the Tasmanian Devil (Sarcophilus harrisii) and devil facial tumour disease. Ecohealth 2007, 4:338-345.
66. Xie W., Wang Y., Huang Y., Yang H., Wang J., Hu Z. Toll-like receptor 2 mediates invasion via activating NF-kappaB in MDA-MB-231 breast cancer cells. Biochem. Biophys. Res. Commun. 2009, 379:1027-1032.
67. Yamamoto M., Sato S., Hemmi H., Hoshino K., Kaisho T., Sanjo H., Takeuchi O., Sugiyama M., Okabe M., Takeda K., Akira S. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003, 301:640-643.
68. Yamaoka S., Courtois G., Bessia C., Whiteside S.T., Weil R., Agou F., Kirk H.E., Kay R.J., Israel A. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell 1998, 93:1231-1240.
69. Zhu Q., Egelston C., Vivekanandhan A., Uematsu S., Akira S., Klinman D.M., Belyakov I.M., Berzofsky J.A. Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:16260-16265.